Paper34145166
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.
Bryant A and 6 others. Am J Ther, 2021. Cited by 157 papers, by iCite. Under an expression of concern.
Cite this record
ConductScience Library. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Papers, record 34145166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34145166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Ivermectin | Major topic |
| COVID-19 Drug Treatment | Major topic |
| Antiviral Agents | |
| Humans | |
| SARS-CoV-2 | |
| Treatment Outcome |
Source PubMed
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Expression of concern in | 35142702 | Expression of Concern for Bryant a, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021;28(4): e434-e460. | https://conductscience.org/library/papers/35142702 | PubMed |
| Comment in | 34469921 | Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460, July 2021. | https://conductscience.org/library/papers/34469921 | PubMed |
| Comment in | 34994351 | Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19. | https://conductscience.org/library/papers/34994351 | PubMed |
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32678530 | Dexamethasone in Hospitalized Patients with Covid-19. | N Engl J Med | 2021 | https://conductscience.org/library/papers/32678530 | PubMed |
| 2 | 12362927 | Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. | J Clin Pharmacol | 2002 | https://conductscience.org/library/papers/12362927 | PubMed |
| 3 | 33542646 | Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women. | Int J Gen Med | 2021 | https://conductscience.org/library/papers/33542646 | PubMed |
| 4 | 32895293 | Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. | Open Heart | 2020 | https://conductscience.org/library/papers/32895293 | PubMed |
| 5 | 32378737 | The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. | Clin Pharmacol Ther | 2020 | https://conductscience.org/library/papers/32378737 | PubMed |
| 6 | 20623822 | Meta-analysis for rare events. | Stat Med | 2010 | https://conductscience.org/library/papers/20623822 | PubMed |
| 7 | 31960060 | Safety of high-dose ivermectin: a systematic review and meta-analysis. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/31960060 | PubMed |
| 8 | 22143403 | Bayesian analysis on meta-analysis of case-control studies accounting for within-study correlation. | Stat Methods Med Res | 2015 | https://conductscience.org/library/papers/22143403 | PubMed |
| 9 | 34483029 | Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. | J Infect Chemother | 2021 | https://conductscience.org/library/papers/34483029 | PubMed |
| 10 | 34265236 | Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India. | J Pharm Pharm Sci | 2021 | https://conductscience.org/library/papers/34265236 | PubMed |
| 11 | 20827667 | Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. | Stat Med | 2010 | https://conductscience.org/library/papers/20827667 | PubMed |
| 12 | 33454964 | Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortality. | Br J Dermatol | 2021 | https://conductscience.org/library/papers/33454964 | PubMed |
| 13 | 32942671 | Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? | Cells | 2020 | https://conductscience.org/library/papers/32942671 | PubMed |
| 14 | 3802833 | Meta-analysis in clinical trials. | Control Clin Trials | 1986 | https://conductscience.org/library/papers/3802833 | PubMed |
| 15 | 32559771 | The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin. | Drug Res (Stuttg) | 2020 | https://conductscience.org/library/papers/32559771 | PubMed |
| 16 | 33065103 | Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. | Chest | 2021 | https://conductscience.org/library/papers/33065103 | PubMed |
| 17 | 34249367 | Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. | New Microbes New Infect | 2021 | https://conductscience.org/library/papers/34249367 | PubMed |
| 18 | 33599247 | Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. | QJM | 2022 | https://conductscience.org/library/papers/33599247 | PubMed |
| 19 | 35314650 | Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial. | Infect Dis Rep | 2022 | https://conductscience.org/library/papers/35314650 | PubMed |
| 20 | 31349391 | MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. | Res Synth Methods | 2019 | https://conductscience.org/library/papers/31349391 | PubMed |
Cited by124
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 157 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42890391 | Toxicological Vulnerabilities and Emerging Safety Signals in Modified mRNA Vaccine Technology: A Narrative Review of the COVID-19 Experience. | J Toxicol | 2026 | https://conductscience.org/library/papers/42890391 | PubMed |
| 42426878 | Translational stewardship in pandemic therapeutics: ivermectin, evidentiary misalignment, and the propagation of constraints. | J Transl Med | 2026 | https://conductscience.org/library/papers/42426878 | PubMed |
| 41918076 | The role of ivermectin in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/41918076 | PubMed |
| 41012540 | A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41012540 | PubMed |
| 40723800 | Immune Signatures in Post-Acute Sequelae of COVID-19 (PASC) and Myalgia/Chronic Fatigue Syndrome (ME/CFS): Insights from the Fecal Microbiome and Serum Cytokine Profiles. | Biomolecules | 2025 | https://conductscience.org/library/papers/40723800 | PubMed |
| 40529997 | What Lessons can Be Learned From the Management of the COVID-19 Pandemic? | Int J Public Health | 2025 | https://conductscience.org/library/papers/40529997 | PubMed |
| 40426524 | Repurposing Anthelmintic Drugs for COVID-19 Treatment: A Comprehensive Meta-Analysis of Randomized Clinical Trials on Ivermectin and Mebendazole. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40426524 | PubMed |
| 40327060 | Ivermectin repurposing for COVID-19: pharmacological and bibliometric analysis. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40327060 | PubMed |
| 40124821 | Ivermectin as a Treatment Modality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Up-To-Date RCTs. | Indian J Community Med | 2025 | https://conductscience.org/library/papers/40124821 | PubMed |
| 40006532 | Experimental Investigation into the Design, Optimization, Toxicity, and Anti-Viral Efficacy of Proliposomes Loaded with Ivermectin Against Infectious Bronchitis Virus Using an Embryonated Chicken Egg Model. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40006532 | PubMed |
| 39791740 | The Ivermectin Related Compound Moxidectin Can Target Apicomplexan Importin α and Limit Growth of Malarial Parasites. | Cells | 2025 | https://conductscience.org/library/papers/39791740 | PubMed |
| 39744515 | Non-spike protein inhibition of SARS-CoV-2 by natural products through the key mediator protein ORF8. | Mol Biol Res Commun | 2025 | https://conductscience.org/library/papers/39744515 | PubMed |
| 39726468 | Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients. | Cureus | 2024 | https://conductscience.org/library/papers/39726468 | PubMed |
| 39706537 | Trial sequential analysis involving same-year studies requires careful temporal ordering. | J Clin Epidemiol | 2025 | https://conductscience.org/library/papers/39706537 | PubMed |
| 39654597 | Medical Ethics and Informed Consent to Treatment: Past, Present and Future. | Cureus | 2024 | https://conductscience.org/library/papers/39654597 | PubMed |
| 39460768 | Repositioning of Antibiotics in the Treatment of Viral Infections. | Curr Microbiol | 2024 | https://conductscience.org/library/papers/39460768 | PubMed |
| 39457519 | Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials. | Biomedicines | 2024 | https://conductscience.org/library/papers/39457519 | PubMed |
| 39452140 | Unveiling the Interplay-Vitamin D and ACE-2 Molecular Interactions in Mitigating Complications and Deaths from SARS-CoV-2. | Biology (Basel) | 2024 | https://conductscience.org/library/papers/39452140 | PubMed |
| 39292387 | Following the Science in the Age of COVID-19. | J Med Humanit | 2026 | https://conductscience.org/library/papers/39292387 | PubMed |
| 39254115 | Toxicologic Pathology Forum: mRNA Vaccine Safety-Separating Fact From Fiction. | Toxicol Pathol | 2024 | https://conductscience.org/library/papers/39254115 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 | NCBI Gene |
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34145166
GET https://conductscience.org/api/papers/v1/34145166/references?page=2